Grand Pharmaceutical Group Ltd banner
G

Grand Pharmaceutical Group Ltd
HKEX:512

Watchlist Manager
Grand Pharmaceutical Group Ltd
HKEX:512
Watchlist
Price: 6.22 HKD -2.96%
Market Cap: HK$22.1B

EV/IC

1
Current
16%
More Expensive
vs 3-y average of 0.9

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
1
=
Enterprise Value
HK$24.5B
/
Invested Capital
HK$21.2B

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
1
=
Enterprise Value
HK$24.5B
/
Invested Capital
HK$21.2B

Valuation Scenarios

Grand Pharmaceutical Group Ltd is trading above its 3-year average

If EV/IC returns to its 3-Year Average (0.9), the stock would be worth HK$5.36 (14% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-50%
Maximum Upside
No Upside Scenarios
Average Downside
20%
Scenario EV/IC Value Implied Price Upside/Downside
Current Multiple 1 HK$6.22
0%
3-Year Average 0.9 HK$5.36
-14%
5-Year Average 0.9 HK$5.54
-11%
Industry Average 1 HK$5.95
-4%
Country Average 0.5 HK$3.13
-50%

Forward EV/IC
Today’s price vs future invested capital

Not enough data available to calculate forward EV/IC

Peer Comparison

All Multiples
EV/IC
P/E
All Countries
Close
Market Cap EV/IC P/E
HK
Grand Pharmaceutical Group Ltd
HKEX:512
21.8B HKD 1 16.9
US
Eli Lilly and Co
NYSE:LLY
883B USD 9.2 42.8
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 3.5 26.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 2.9 20.1
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 3.7 28
US
Merck & Co Inc
NYSE:MRK
270.2B USD 2.6 14.8
CH
Novartis AG
SIX:NOVN
216.3B CHF 2.9 20.7
IE
Endo International PLC
LSE:0Y5F
244.4B USD 56 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 2.6 11.8
US
Pfizer Inc
NYSE:PFE
151.8B USD 1.1 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 2 17.3
P/E Multiple
Earnings Growth PEG
HK
G
Grand Pharmaceutical Group Ltd
HKEX:512
Average P/E: 21.8
16.9
18%
0.9
US
Eli Lilly and Co
NYSE:LLY
42.8
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.3
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
US
Merck & Co Inc
NYSE:MRK
14.8
14%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.8
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.5
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
16%
1.1

Market Distribution

Higher than 73% of companies in Hong Kong
Percentile
73nd
Based on 1 589 companies
73nd percentile
1
Low
0 — 0.3
Typical Range
0.3 — 0.9
High
0.9 —
Distribution Statistics
Hong Kong
Min 0
30th Percentile 0.3
Median 0.5
70th Percentile 0.9
Max 59 382.5

Grand Pharmaceutical Group Ltd
Glance View

Market Cap
22.1B HKD
Industry
Pharmaceuticals

Grand Pharmaceutical Group Ltd. stands as a significant player in the pharmaceutical industry, strategically positioned in the bustling hub of the Asia-Pacific region. Founded with a vision to harness scientific innovation for healing, the company has diligently expanded its reach and capabilities over the years. Grand Pharma is meticulously structured around three core segments: Medicine and Healthcare, Biopharmaceutical Manufacturing, and Medical Devices. In the Medicine and Healthcare segment, it advances an extensive portfolio of both proprietary and generic drugs. This segment alone accounts for a substantial portion of its revenue, capitalizing on its adeptness in research and development to maintain a robust pipeline of products. By continuously innovating and seeking to meet unmet medical needs, Grand Pharma sustains its competitive edge in the market. Their Biopharmaceutical Manufacturing segment shines brightly as a beacon of future growth, showcasing their commitment to biotechnology. Here, Grand Pharmaceutical leverages cutting-edge biotechnologies to develop therapies targeting a range of complex diseases. This segment is noted for its high-margin potential, driven by the increasing global demand for biologics. Furthermore, their Medical Devices segment complements the pharmaceutical operations by delivering state-of-the-art products in areas such as cardiovascular health and surgical equipment. By maintaining a balanced and diversified portfolio across these business areas, Grand Pharmaceutical effectively mitigates risks and capitalizes on emerging trends in global healthcare markets. Through astute strategic planning and an unwavering commitment to quality and innovation, the company fortifies its position as a leader in the field, continually reinvesting its profits to further enhance its offerings and broaden its impact.

Intrinsic Value
5.88 HKD
Overvaluation 6%
Intrinsic Value
Price HK$6.22
G
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett